Clinical Trial Update: A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ixazomib citrate as maintenance therapy after autologous stem cell transplant in multiple myeloma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ixazomib citrate (Ixazomib)

Snippet

Sponsor: Takeda | Conditions: Multiple Myeloma, Autologous Stem Cell Transplant | Phase 3 | Status: COMPLETED | Results posted: 2019-05-07